What Do Analysts Suggest For Regeneron Pharmaceuticals, Inc. (REGN)

0
10

Regeneron Pharmaceuticals, Inc. (REGN) will report its next earnings on Aug 03 BMO. The company reported the earnings of $4.17/Share in the last quarter where the estimated EPS by analysts was $3.17/share. The difference between the expected and actual EPS was $1/share, which represents an Earnings surprise of 31.5%.

Many analysts are providing their Estimated Earnings analysis for Regeneron Pharmaceuticals, Inc. and for the current quarter 22 analysts have projected that the stock could give an Average Earnings estimate of $3.83/share. These analysts have also projected a Low Estimate of $3.2/share and a High Estimate of $4.57/share.

In case of Revenue Estimates, 19 analysts have provided their consensus Average Revenue Estimates for Regeneron Pharmaceuticals, Inc. as 1.46 Billion. According to these analysts, the Low Revenue Estimate for Regeneron Pharmaceuticals, Inc. is 1.34 Billion and the High Revenue Estimate is 1.57 Billion. The company had Year Ago Sales of 1.22 Billion.

These analysts also forecasted Growth Estimates for the Current Quarter for REGN to be 22.4%. They are projecting Next Quarter growth of 29.6%. For the next 5 years, Regeneron Pharmaceuticals, Inc. is expecting Growth of 18.37% per annum, whereas in the past 5 years the growth was 34.03% per annum.

Some buy side analysts are also providing their Analysis on Regeneron Pharmaceuticals, Inc., where 8 analysts have rated the stock as Strong buy, 5 analysts have given a Buy signal, 12 said it’s a HOLD and 1 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Regeneron Pharmaceuticals, Inc. might touch $605 high while the Average Price Target and Low price Target is $498.65 and $327 respectively.

The Relative Volume of the company is 2.38 and Average Volume (3 months) is 830.99 million. The company’s P/E (price to earnings) ratio is 44.68 and Forward P/E ratio of 26.79.

The company shows its Return on Assets (ROA) value of 15.5%. The Return on Equity (ROE) value stands at 23.9%. While it’s Return on Investment (ROI) value is 18.2%.

While looking at the Stock’s Performance, Regeneron Pharmaceuticals, Inc. currently shows a Weekly Performance of -11.68%, where Monthly Performance is -3.25%, Quarterly performance is -6.53%, 6 Months performance is 14.46% and yearly performance percentage is 15.78%. Year to Date performance value (YTD perf) value is 21.25%. The Stock currently has a Weekly Volatility of 2.94% and Monthly Volatility of 2.34%.